Keywords
diabetes mellitus
wound cytology
granulocyte-colony-stimulating factor
How to Cite
Abstract
Background. Purulent-inflammatory diseases of soft tissues in patients with diabetes mellitus proceed quite aggressively and, according to the standards, characteristic of acute infections of soft tissues without diabetes mellitus can inconsistently affect the fate of patients with concomitant diabetes mellitus. The study aimed to study the features of the cytological picture of wounds in patients with purulent-inflammatory diseases of soft tissues on the background of diabetes mellitus after the use of granulocyte-colony-stimulating factor.
Methods. In 132 patients with purulent-inflammatory diseases of soft tissues on the background of diabetes mellitus, cytological studies of the wound were performed. The background materials of the cytological preparation were detritus, small protein grains, fat drops, crystals, hematoidin, cholesterol, etc. The cytological material was stained with azure-eosin mixtures.
Results. The results obtained indicate that along with cellular elements in the morphology of the wound in patients with purulent-inflammatory diseases of soft tissues against the background of diabetes mellitus, other representatives of the cytological picture also play a significant role. The results of a cytological study of smears-imprints of a purulent inflammatory wound of soft tissues in patients with diabetes mellitus showed that the microscopic picture of the smear was characterized, first, by the presence of a microbial factor in combination with background elements.
Conclusion. Under the influence of the preparation of granulocyte-colony-stimulating factor in patients with purulent-inflammatory diseases of soft tissues against the background of diabetes mellitus, it increases the number of neutrophils and lymphocytes, and increases their phagocytic activity in the wound.
References
Okhunov A.O., Babadzhanov B.D., Kasymov U.K. et al. Modern principals of antibacterial therapy of suppurative-septic diseases | Sovremennye printsipy antibakterial'noi terapii gnoino-septicheskikh zabolevanii. Likars'ka sprava / Ministerstvo okhorony zdorov'ia Ukraïny, 2003, (7), pp. 70–73.
Okhunov A.O., Abdurahmanov F.M., Boboev Q. et al. The choice of method of surgical correction of complicated forms of diabetes type 2. International journal of diabetes and metabolic disorders, 2019, 4 (4), 1-3
Dale D.C., Bonilla M.A., Davis M.W. et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood. 1993; 81:2496-2502.
Hartmann L.C., Tschetter L.K., Habermann T.M. et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med. 1997; 336:1776-1780.
Dale D.C., Crawford J., Klippel Z. et al. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer. 2018; 26:7-20.
Sörgel F., Lerch H., Lauber T. et al. Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product. Bio Drugs. 2010; 24:347.
Van Agthoven M., Busschbach J., Fokkens W.J. et al. Quality of life and costs of filgrastim (g-csf) treatment in patients with persistent chronic rhinosinusitis. Institute for Medical Technology Assessment. Report number 00.53.
Blackstone E.A., Joseph P.F. The economics of biosimilars. Am Health Drug Benefits. 2013; 6:469-478.
Smith G.M., Child J.A., Cullen M.H. et al. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group. Hematol Oncol. 1996 Dec;14(4):193-201. doi: 10.1002/(SICI)1099-1069(199612)14:4<193: AID-HON590>3.0.CO;2-G.
Kuderer N.M., Dale D.C., Crawford J. et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006; 106:2258-2266.
Tokumo K., Masuda T., Miyama T. et al. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma. Lung Cancer. 2018; 119:21-24.
Remick S.C., Sedransk N., Haase R.F. et al. Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up. Am J. Hematol. 2001 Mar;66(3):178-88. doi: 10.1002/1096-8652(200103)66:3<178: aid-ajh1042>3.0.co;2-h.
Trillet-Lenoir V., Green J., Manegold C. et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur. J. Cancer. 1993;29A:319-324.
Smith T.J., Bohlke K., Lyman G.H. et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J. Clin. Oncol. 2015; 33:3199-3212.
Crawford J., Dale D.C., Kuderer N.M. et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J. Natl. Compr. Canc. Netw. 2008; 6:109-118.
Publicover A., Richardson D.S., Davies A. et al. Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. Br J Haematol. 2013; 162:107-111.
Altwairgi A.K., Hopman W.M., Mates M. et al. Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia. Curr Oncol. 2013;20: e171-e179.
Fitzhugh C.D., Hsieh M.M., Bolan C.D. et al. Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium? Cytotherapy. 2009; 11:464-471.
Wang L., Baser O., Kutikova L. et al. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomised controlled trials. Support Care Cancer. 2015; 23:3131-3140.
Rak Tkaczuk K.H., Jacobs I.A. Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and “emergency” hematopoiesis. Biosimilars in oncology: from development to clinical practice. Semin Oncol. 2014;41: S3-S12.
Anderlini P., Przepiorka D., Seong D. et al. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion. 1996; 36:590-595.
Morphofunctional assessment of the features of manifestations of acute purulent-destructive lung diseases / A Okhunov // Journal of Educational & Scientific Medicine 1 (1), 24-31.
Local cytokine therapy for diabetic foot syndrome / AO Okhunov // Central Asian Journal of Medicine 1 (3), 22-32.
About predatory publishing – what it is and how to recognize it? / FL Azizova, AO Okhunov, NS Khudaibergenova // Journal of Educational and Scientific Medicine 1 (3), 45-55.
Is it necessary to revise the methods of treatment of acute purulent destructive lung diseases if they are sequels after COVID-19? / AO Okhunov // Eur. Chem. Bull. 12 (13), 1130-1136.
Comparative Evaluation of the Effectiveness of Methods for the Treatment of Surgical Soft Tissue Infection / AO Okhunov // Int J Clin Microbiol Biochem Technol., 5-11.
Use of Vacuum in The Treatment of Acute Lung Abscess in Patients with Diabetes / AO Oxunov, SA Xamdamov // Texas Journal of Medical Science, 143-146.
Clinical and Morphological Substantiation of the Choice of Treatment Method for Diabetic Foot Syndrome / A Okhunov, S Atakov, I Sattarov, K Matmuratov, U Kasimov // European Chemical Bulletin 12 (7), 4585-4597.